Patrick Kee

Patrick Kee

Auto-generated profile, based on publicly available information

Patrick Kee

The University of Texas Health Science Center at Houston

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Immune Network
Verified
Journal Article
Open access
PDF file
YKYoung Uk Kim
Young Uk Kim
PKPatrick Kee
Patrick Kee
DDDelia Danila
Delia Danila
BTBa-Bie Teng
Ba-Bie Teng
Kim YU, et al. Immune Netw. 2019 Dec;19(6):e41. https://doi.org/10.4110/in.2019.19.e41

1 February 2013 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
YRYonghoon Rim
Yonghoon Rim
SLSusan T. Laing
Susan T. Laing
PKPatrick Kee
Patrick Kee
DMDavid D. McPherson
David D. McPherson
HKHyunggun Kim
Hyunggun Kim

1 June 2014 in Ultrasound in Medicine & Biology
Verified
Journal Article
Closed access
PKPatrick H. Kee
Patrick H. Kee
HKHyunggun Kim
Hyunggun Kim
SHShaoling Huang
Shaoling Huang
SLSusan T. Laing
Susan T. Laing
MMMelanie R. Moody
Melanie R. Moody
DMDavid D. McPherson
David D. McPherson

1 January 2008 in Journal of Liposome Research
Verified
Journal Article
Closed access
PKPatrick H. Kee
Patrick H. Kee
TATodd A. Abruzzo
Todd A. Abruzzo
DSDenise A.B. Smith
Denise A.B. Smith
JKJonathan Kopechek
Jonathan Kopechek
BWBoyu Wang
Boyu Wang
DMDavid D. McPherson
David D. McPherson
Development of encapsulated therapeutics that could be released upon ultrasound exposure has strong implications for enhancing drug effects at the target site. We have developed echogenic liposomes (ELIP) suitable for ultrasound imaging of blood flow and ultrasound-mediated intravascular drug release. Papaverine was chosen as the test drug because its clinical application requires high concentration in the target vascular bed but low concentration in the systemic circulation. the procedure for preparation of standard ELIP was modified by including Papaverine hydrochloride in the lipid hydration solution, followed by three freeze-thaw cycles to increase encapsulation of the drug. Sizing and encapsulation pharmacokinetics were performed using a Coulter counter and a phosphodiesterase activity assay. Stability of Papaverine-loaded ELIP (PELIP) was monitored with a clinical diagnostic ultrasound scanner equipped with a linear array transducer at a center frequency of 4.5 MHz by assessing the mean digital intensity within a region of interest over time. The stability of PELIP was compared to those of standard ELIP and Optison. relative to standard ELIP, PELIP were larger (median diameter = 1.88 +/- 0.10 microm for PELIP vs 1.08 +/- 0.15 microm for ELIP) and had lower Mean Gray Scale Values (MGSV) (92 +/- 24.8 for PELIP compared to 142.3 +/- 10.7 for ELIP at lipid concentrations of 50 microg/ml). The maximum loading efficiency and mean encapsulated concentration were 24% +/- 7% and 2.1 +/- 0.7 mg/ml, respectively. Papaverine retained its phosphodiesterase inhibitory activity when associated with PELIP. Furthermore, a fraction of this activity remained latent until released by dissolution of liposomal membranes with detergent. The stability of both PELIP and standard ELIP were similar, but both are greater than that of Optison. our results suggest that PELIP have desirable physical, biochemical, biological, and acoustic characteristics for potential in vivo administration and ultrasound-controlled drug delivery.

10 October 2014 in Molecular Imaging and Biology
Verified
Journal Article
Closed access
PDF file
PKPatrick Kee
Patrick Kee
VBVaishali Bagalkot
Vaishali Bagalkot
EJEvan Johnson
Evan Johnson
DDDelia Danila
Delia Danila

Verified
Journal Article
Open access
PDF file
RSRosemeire Silva
Rosemeire Silva
RGRicardo J. Giordano
Ricardo J. Giordano
PGPaulo S. Gutierrez
Paulo S. Gutierrez
VRViviane Z. Rocha
Viviane Z. Rocha
MRMartina Rudnicki
Martina Rudnicki
JKJorge Kalil
Jorge Kalil
The purpose of our work was to select phages displaying peptides capable of binding to vascular markers present in human atheroma, and validate their capacity to target the vascular markers in vitro and in low-density lipoprotein receptor knockout (LDLr−/−) mouse model of atherosclerosis. By peptide fingerprinting on human atherosclerotic tissues, we selected and isolated four different peptides sequences, which bind to atherosclerotic lesions and share significant similarity to known human proteins with prominent roles in atherosclerosis. The CTHRSSVVC-phage peptide displayed the strongest reactivity with human carotid atherosclerotic lesions (p < 0.05), when compared to tissues from normal carotid arteries. This peptide sequence shares similarity to a sequence present in the fifth scavenger receptor cysteine-rich (SRCR) domain of CD163, which appeared to bind to CD163, and subsequently, was internalized by macrophages. Moreover, the CTHRSSVVC-phage targets atherosclerotic lesions of a low-density lipoprotein receptor knockout (LDLr−/−) mouse model of atherosclerosis in vivo to High-Fat diet group versus Control group. Tetraazacyclododecane-1,4,7,10-tetraacetic acid-CTHRSSVVC peptide (DOTA-CTHRSSVVC) was synthesized and labeled with 111InCl3 in >95% yield as determined by high performance liquid chromatography (HPLC), to validate the binding of the peptide in atherosclerotic plaque specimens. The results supported our hypothesis that CTHRSSVVC peptide has a remarkable sequence for the development of theranostics approaches in the treatment of atherosclerosis and other diseases.